DSS Receives New York Stock Exchange Notice Regarding Late Form 10-Q Filing
August 30, 2022 16:45 ET
|
DSS, Inc.
ROCHESTER, N.Y., Aug. 30, 2022 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating businesses within nine divisions and strategically acquiring and developing...
Impact BioMedical Develops Quantum Antihistamine
July 26, 2022 08:00 ET
|
DSS, Inc.
ROCHESTER, N.Y., July 26, 2022 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating businesses within nine divisions and strategically acquiring and developing...
DSS Announces Licensing of Impact BioMedical’s Linebacker Portfolio to ProPhase Labs
July 21, 2022 17:00 ET
|
DSS, Inc.
ROCHESTER, N.Y., July 21, 2022 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating businesses within nine divisions and strategically acquiring and developing...
DSS Strengthens and Expands Board with Appointment of Two Independent Directors
July 13, 2022 08:00 ET
|
DSS, Inc.
ROCHESTER, N.Y., July 13, 2022 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating businesses within nine divisions and strategically acquiring and developing...
Impact BioMedical Announces License Agreement with ProPhase Labs to Produce and Distribute Viral-Fighting Compound Equivir
June 28, 2022 08:00 ET
|
DSS, Inc.
HENRIETTA, N.Y., June 28, 2022 (GLOBE NEWSWIRE) -- Impact Biomedical, Inc., a wholly owned subsidiary of DSS, Inc. (NYSE American: DSS), along with its scientific research partner Global Research...
DSS’s Impact BioMedical Receives China Patent for its Functional Fragrance Formulation Mosquito Repellant
June 07, 2022 07:00 ET
|
DSS, Inc.
HENRIETTA, N.Y., June 07, 2022 (GLOBE NEWSWIRE) -- DSS, Inc. (“DSS” or the “Company”) (NYSE American: DSS), a multinational company operating businesses within nine divisions and strategically...
DSS, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report®
May 06, 2022 08:30 ET
|
DSS, Inc.
ROCHESTER, N.Y., May 06, 2022 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating businesses within nine divisions and strategically acquiring and developing assets...
Impact BioMedical’s Proprietary Equivir Compound to Treat Viral Infection Receives Clean Patentability Report from World Intellectual Property Organization’s ISA Division
March 03, 2022 08:00 ET
|
DSS, Inc.
ROCHESTER, N.Y., March 03, 2022 (GLOBE NEWSWIRE) -- Impact Biomedical, Inc., a wholly owned subsidiary of DSS, Inc. (NYSE American: DSS), along with its scientific research partner Global Research...
CORRECTION - DSS Announces Letter to Shareholders
February 28, 2022 17:15 ET
|
DSS, Inc.
ROCHESTER, N.Y., Feb. 28, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by DSS, Inc. (NYSE American: DSS), please note that in paragraph fourteen, [With more...
DSS Announces Letter to Shareholders
February 28, 2022 08:00 ET
|
DSS, Inc.
ROCHESTER, N.Y., Feb. 28, 2022 (GLOBE NEWSWIRE) -- DSS, Inc. (“DSS” or the “Company”) (NYSE American: DSS), a multinational company with ten operating business lines in diverse, high-growth...